This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 6 September 2002 (06.09.2002)

PCT

(10) International Publication Number WO 02/068388 A3

(51) International Patent Classification⁷: 31/505, C07D 401/06, 401/14, 451/02

(21) International Application Number:

A61K 31/445,

PCT/US02/05724

- (22) International Filing Date: 25 February 2002 (25.02.2002)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/272,258 28 February 200 60/300,118 22 June 200

28 February 2001 (28.02.2001) US 22 June 2001 (22.06.2001) US

- (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): UJJAINWALLA, Feroze [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). CHU, Lin [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). GOULET, Mark, T. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). LEE, Bonnie [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). WARNER, Daniel [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). WYVRATT, Matthew, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

- (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 13 March 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Z/0683888 A

(54) Title: ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS

(57) Abstract: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

International application No.
PCT/US02/05724

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) :IPC7 A61K 31/445, 31/505; C07D 401/06, 401/14, 451/02 US CL :Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification syn	mbols)			
U.S. : 514/256, 316, 318, 326; 544/335; 546/124, 187, 193; 548/958				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CASstructure EAST/WEST-subclass, melanocortin				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category Citation of document, with indication, where appropriate, of the relev	vant passages Relevant to claim N	Vo.		
Y US 6,166,037 A (BUDHU et al.) 26 December 2000 document, especially column 75-76 formula XXXIII an	0, see entire 1-15, 21, 28 and XXXIX.			
Y Database CAPLUS on STN (Columbus, OH, USA) No. 1 'MC3-R as a novel target for antiinflammatory therapy Getting et al. 2000, vol.13, No.1, pages 19-27, see entire	v' Abstract.			
108:150205, 'Highly regioselective synthesis of t pyrrolidines by 1,2-cycloaddition' Chem. Phar. bull. 19	Database CAPLUS on STN (Columbus, OH, USA) No. 108:150205, 'Highly regioselective synthesis of trisubstituted pyrrolidines by 1,2-cycloaddition' Chem. Phar. bull. 1987, vol. 35, no. 7, pages 2646-55, see compounds with RN attached.			
X Further documents are listed in the continuation of Box C. See patent family annex.				
Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "A" description of cited documents: "A" later document published after the international filing date or priority date and not in conflict with the application but cited to understand to be of particular relevance		7		
E" carlier document published on or after the international filing data. "X" document of particular relevance; the claimed invention cannot be		.		
"L" document which may threw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other				
*O" document referring to an oral disclosure, use, exhibition or other with one or me means obvious to a per	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a parson skilled in the art			
"P" document published prior to the international filing date but later "&" document member of the same patent family than the priority date claimed				
_	Date of mailing of the international search report 10 DEC 2007			
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Authorized officer CELIA CHANG	Authorized officer Januari Ford			
Telephone No. (703) 305-3230 Telephone No. (703) 308-1235 Telephone No. (703) 308-1235				

International application No. PCT/US02/05724

C (Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No
Х, Р	Database CAPLUS on STN (Columbus, OH, USA) No. 135:166844, 'Preparation of piperazinyl and piperidinyl ketones useful for treating or prevention neuronal damage and for stimulating nerve growth', Tomlinson et al, August 2001, see compounds of RN attached.		1-15, 21, 28

International application No.
PCT/US02/05724

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)				
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:				
S. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)				
This International Searching Authority found multiple inventions in this international application, as follows:				
Please See Extra Sheet.				
1. X As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.				
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:				
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is				
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.				

International application No. PCT/US02/05724

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

514/256, 316, 318, 326; 544/335; 546/124, 187, 193; 548/953

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-10, 16-21 in part (r=1, s=1 or r=2, s=0), 11-15 and 28, drawn to piperidinyl pyrrolidinyl compounds composition and method of use.

Group II, claims 1-10, 16-21 in part (r=2, s=1, r=1, s=2), drawn to piperidinyl piperidines, composition and method of use.

Group III, claims 1-10, 16-21 in part (r=2, s=2), drawn to azepidinyl compounds, composition and method of use. Group IV, claims 1-10, 16-21 in part (r=1, s=0), drawn to four membered ring nitrogen containing compounds, composition and method of use.

Group V, claims 22, 26-27, drawn to composition and method of treating diabetes or obesity. Group VI, claims 28-25, drawn to composition and method of treating erectile dysfunction.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the compounds of groups I-IV have disintct structure and at least one of the Markush alternatives is not novel (see CA 130:223167RN 221142-59-2 anticipated group I). Groups V-VI are drawn to combination of active ingredients for treating disease which are not dependent on the novelty of the compounds for patentability. Under Rule 13.2 Annex B Markush Practice part I, paragraph (f)(i)(B)(1)v when dealing with alternatives, if it can be shown that at least one Markush alternative is not novel over the prior art, the question of unity of invention shall be reconsidered by the examiner

